ClinicalTrials.gg

Program

PG4 Multivalent Vaccine

Its studies are mostly in Pneumococcal Infections, led by Pfizer.

Furthest: phase 3, since Aug 26, 20261 company-led study, 1 open or runningNext primary completion: Apr 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 3since Aug 26, 2026Aug 26, 2026Apr 26, 2027phase 3 · NCT07794748

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2026First study: phase 3 study in Pneumococcal InfectionsFirst studyNCT07794748 · 4,701 enrolled · United States

Ahead

  1. Apr 26, 2027Primary completion: phase 3 study in Pneumococcal InfectionsNCT07794748

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“PG4 Multivalent Vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07794748Pneumococcal Infections · United States3Active, not recruitingApr 26, 20274,701

How it is read

Names in the registry

  • “PG4 Multivalent Vaccine”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.